Odabasi Ali R, Yuksel Hasan, Karul Aslihan, Kozaci Didem, Sezer Selda D, Onur Ergun
Adnan Menderes Universitesi, Tip Fakultesi, Kadin Hastaliklari ve Dogum Anabilim Dali 09100, Aydin, Turkey.
Saudi Med J. 2007 Jun;28(6):855-61.
To compare the effects of standard and low dose of 17beta-estradiol/norethisterone acetate (E2/NETA) on body composition and leptin in postmenopausal women at risk of body mass index (BMI) -and waist girth (WG) related cardiovascular and metabolic disease.
Ninety postmenopausal women aged 45-55 years with BMI >or= 25 kg/m2 participated in this 6-month prospective, randomized, single-blinded and controlled study, conducted between September 2004 and April 2006 at Adnan Menderes University Hospital. According to their WG, the subjects were divided into 2 risk groups: WG <88 cm (Group increased risk [IR], n=48) or WG >or= 88 cm (Group high risk [HR], n=42). The subjects in each group were equally assigned to receive standard or low dose of E2/NETA (2 mg E2/1 mg NETA, or 1 mg E2/0.5 mg NETA). Accordingly, the 2 groups were divided into 4 subgroups. Serum leptin levels (SLLs), body weight/height, waist/hip girth, BMI and waist-to-hip ratio were evaluated before and after therapy.
In the Group IR, WG decreased significantly only in low dose subgroup. In the Group HR, both standard and low dose subgroups had a significant reduction in WG. Those who had WG >or= 88 cm showed more reduction than those who had WG <88 cm in response to both doses of E2/NETA, insignificantly. Basal SLLs had a significant correlation with body weight, BMI and WG.
Oral standard and low dose E2/NETA reduce WG and attenuate the BMI- and waist girth- related risk of cardiovascular and metabolic diseases in postmenopausal women.
比较标准剂量和低剂量的17β-雌二醇/醋酸炔诺酮（E2/NETA）对有体重指数（BMI）和腰围（WG）相关心血管及代谢疾病风险的绝经后女性身体成分和瘦素的影响。
90名年龄在45 - 55岁、BMI≥25 kg/m²的绝经后女性参与了这项为期6个月的前瞻性、随机、单盲对照研究，该研究于2004年9月至2006年4月在阿德南·门德雷斯大学医院进行。根据腰围，受试者被分为2个风险组：腰围<88 cm（增加风险组[IR]，n = 48）或腰围≥88 cm（高风险组[HR]，n = 42）。每组受试者被平均分配接受标准剂量或低剂量的E2/NETA（2 mg E2/1 mg NETA，或1 mg E2/0.5 mg NETA）。据此，2组又被分为4个亚组。在治疗前后评估血清瘦素水平（SLLs）、体重/身高、腰臀围、BMI和腰臀比。
在IR组中，仅低剂量亚组的腰围显著降低。在HR组中，标准剂量和低剂量亚组的腰围均显著降低。腰围≥88 cm的受试者在两种剂量的E2/NETA治疗下，其腰围的降低幅度比腰围<88 cm的受试者略大，但差异不显著。基础SLLs与体重、BMI和腰围显著相关。
口服标准剂量和低剂量的E2/NETA可降低绝经后女性的腰围，并减轻与BMI和腰围相关的心血管及代谢疾病风险。
Zotero 插件